Status
Conditions
About
The primary goal of this study is to identify patients with RNA expression profiles consistent with eligibility requirements for therapeutic clinical trials across solid tumors. Left-over tumor tissue will be collected from eligible participants for RNA expression analysis using next-generation sequencing.
Full description
The primary goal of this study is to identify patients with RNA expression profiles consistent with eligibility requirements for therapeutic clinical trials across solid tumors. Left-over tumor tissue will be collected from eligible participants for RNA expression analysis using next-generation sequencing.
A parallel study, StrataPATH™ (STR-004-001), has been developed to support therapeutic hypotheses. Participants may be consented and screened for enrollment separately into StrataPATH with an eligible matching biomarker/drug treatment cohort upon positive identification of a relevant expression signature. Treatment effectiveness of antibody drug conjugates and other targeted therapies will be evaluated in these molecularly defined cohorts.
Sex
Ages
Volunteers
Inclusion criteria
Must be ≥18 years of age,
Participant must have pathologically confirmed advanced, metastatic, or recurrent solid tumor,
Measurable disease,
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2,
Participant must meet at least 1 of the following:
Adequate cardiac, bone marrow, organ function & laboratory parameters as determined by the treating physician for potential participation in a clinical trial,
Leftover formalin-fixed, paraffin-embedded (FFPE) tumor tissue available for StrataEXP testing
Exclusion criteria
Loading...
Central trial contact
Melissa Wolfe; Stephanie Bush
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal